Lappe Mark, CEO, reported an open-market or private purchase at Inhibrx Biosciences, Inc. involving 1500.000000 shares for an estimated $148320.45. Reported holdings after the transaction were 737548.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
The shares were purchased in multiple transactions at prices ranging from $98.27 to $99.26 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby under…
These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities o…
The shares were purchased in multiple transactions at prices ranging from $99.335 to $100.00 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby und…
The shares were purchased in multiple transactions at prices ranging from $98.69 to $99.21 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby under…
The shares were purchased in multiple transactions at prices ranging from $101.44 to $101.80 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby und…
These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deeme…
0 other filings
0 recent txs